Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.74 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.71 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11428736 | 0.90 | EPHX2 (0.68) | PTPN1PTPN11PTPN6 | |
| SCHEMBL23880555 | 0.89 | PTPN1 (0.78) | PTPN1PTPN11PTPN6 | |
| SCHEMBL30042099 | 0.86 | PTPN1 (1.00) | PTPN1PTPN11PTPN6 | |
| SCHEMBL23880571 | 0.86 | PTPN1 (1.00) | PTPN1PTPN11PTPN6 | |
| SCHEMBL23880581 | 0.85 | PTPN11 (0.76) | PTPN1PTPN11PTPN6 | |
| SCHEMBL23880564 | 0.85 | PTPN11 (0.76) | PTPN1PTPN11PTPN6 | |
| SCHEMBL23895479 | 0.84 | PTPN11 (1.00) | PTPN1PTPN11PTPN6 | |
| SCHEMBL23895469 | 0.84 | PTPN11 (0.74) | PTPN1PTPN11PTPN6 | |
| SCHEMBL23880574 | 0.84 | PTPN11 (0.64) | PTPN1PTPN11PTPN6 | |
| SCHEMBL23880575 | 0.81 | PTPN11 (0.74) | PTPN1PTPN11PTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115297860-B | Novel N-aryl oxamic acids | 普渡研究基金会 | 2024-10-15 | — | — | CN | disclosed |
| EP-4132523-A1 | NOVEL N-ARYL OXAMIC ACIDS | Purdue Research Foundation (US) | 2023-02-15 | — | — | EP | disclosed |
| CN-115297860-A | Novel N-aryl-oxalamic acids | 普渡研究基金会 | 2022-11-04 | — | — | CN | disclosed |
| US-11192850-B2 | N-aryl oxamic acids | PURDUE RESEARCH FOUNDATION (US) | 2021-12-07 | — | — | US | disclosed |
| US-20210309606-A1 | Novel N-aryl Oxamic Acids | PURDUE RESEARCH FOUNDATION (US) | 2021-10-07 | — | — | US | disclosed |
| US-20210309606-A1 | Novel N-aryl Oxamic Acids | PURDUE RESEARCH FOUNDATION (US) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309606-A1 | Novel N-aryl Oxamic Acids | PTPRB, PTPRO, PTPRM | PTPN1 14/4885PTPN11 23/4885PTPN6 17/4885 |
| US-11192850-B2 | N-aryl oxamic acids | PTPRB, PTPRO, PTPRM | PTPN1 13/4885PTPN11 23/4885PTPN6 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.